Thus, upon verification in future in vivo studies, the CD133 aptamer-mediated delivery of DOX combined with autophagy inhibitor hydroxychloroquine may constitute a novel approach to transarterial chemoembolization to improve the therapeutic outcome of patients with intermediate-stage HCC. The gene discussed is PROM1; the disease is hepatocellular carcinoma.